Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
This study is currently recruiting participants.
Verified February 2013 by Alcon Research
Sponsor:
Alcon Research
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT01697969
First received: September 27, 2012
Last updated: February 27, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Conjunctivitis |
Drug: Olopatadine hydrochloride ophthalmic solution, 0.2% |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% |
Resource links provided by NLM:
Further study details as provided by Alcon Research:
Primary Outcome Measures:
- Patient-Assessed Ocular Itching [ Time Frame: Day 1 ] [ Designated as safety issue: No ]As rated by the patient on a 0-4 scale.
- Patient-Assessed Ocular Itching [ Time Frame: Day 14 ] [ Designated as safety issue: No ]As rated by the patient on a 0-4 scale.
| Estimated Enrollment: | 25 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Pataday
One drop of olopatadine 0.2% once daily in both eyes for 14 days
|
Drug: Olopatadine hydrochloride ophthalmic solution, 0.2%
One drop once daily in both eyes for 14 days
Other Name: PATADAY®
|
Detailed Description:
Heidelberg Retina Tomograph (HRT) will be used to descriptively evaluate the corneal structures and assess the immune cell status of allergic conjunctivitis patients pre and post treatment with olopatadine 0.2% in relation to a normative database.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Read, sign, and date an Ethics Committee reviewed and approved informed consent form.
Females of childbearing potential who:
- Are not breast-feeding;
- Do not intend to become pregnant for the duration of the study;
- Are using adequate birth control methods and agree to continue for the duration of the study.
- Able to read, understand and answer questions by investigator.
- Willing and able to attend all required study visits and follow directions as stipulated by the protocol and investigator.
- History of allergic conjunctivitis (within the past 12 months) and active signs and symptoms of ocular allergies for which treatment is necessary, in the opinion of the investigator.
- Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with or without glasses correction.
- Ocular health within normal limits as determined by the investigator.
- No contact lens wear 14 days prior to enrollment and willing to not wear contact lenses for the duration of the study.
- Willing to follow a 14-day washout period due to contraindicated medication use, if deemed necessary by investigator.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Contraindications or hypersensitivity to the use of the test article or its components.
- Inability or unwillingness to follow all study instructions and complete study visits as required.
- Only one sighted eye or visual acuity not correctable to 20/30 (Snellen) in both eyes at the Screening Visit.
- Ocular trauma within 6 months prior to Visit 1 in either eye.
- Any ocular surgical intervention within six months prior to Visit 1 or anticipation of ocular surgery during the study.
- Presumed or actual ocular infection within 30 days prior to Visit 1.
- Any severe or serious ocular condition or significant illness.
- Any abnormal slit-lamp findings at the time of the Screening Visit.
- Contact lens wear within 14 days prior to the study start and unwillingness to undergo a wash-out period of 14 days; unwilling to not wear contact lenses for the duration of the study.
- Use of over-the-counter (OTC) ocular medications within the past 14 days unless willing to follow wash out period.
- Use of topical or systemic ocular medications requiring longer than a two-week washout period.
- Participation in any other investigational study in the 30-day period before entry into this study (i.e., Visit 1) or concomitantly with this study.
- Women who are pregnant, nursing, or of childbearing potential not utilizing adequate birth control measures.
- Other protocol-defined exclusion criteria may apply.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01697969
Contacts
| Contact: Alcon Call Center | 1-888-241-7629 |
Locations
| United States, Iowa | |
| University of Iowa | Recruiting |
| Iowa City, Iowa, United States, 52242-1091 | |
Sponsors and Collaborators
Alcon Research
Investigators
| Principal Investigator: | Christine Sindt, OD, FAAO | University of Iowa |
| Study Director: | Pam Kaur, MS PhD | Alcon Research |
More Information
No publications provided
| Responsible Party: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT01697969 History of Changes |
| Other Study ID Numbers: | M-12-047 |
| Study First Received: | September 27, 2012 |
| Last Updated: | February 27, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Alcon Research:
|
allergic conjunctivitis Pataday Olopatadine |
Additional relevant MeSH terms:
|
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Olopatadine Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Anti-Allergic Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Antirheumatic Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013